PharmaCyte Biotech (PMCB)
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulat...
- Open
- 0.5308
- High
- 0.5324
- Low
- 0.5044
- Prev. Close
- 0.5324
- Volume
- 42.82K
- Turnover
- 22.03K
- Avg Price
- 0.5144
- Bid/Ask Ratio
- 65.75%
- Amplitude
- 5.26%
- 52wk High
- 1.5100
- Volume Ratio
- 0.42
- Turnover Ratio
- 0.43%
PharmaCyte Biotech Analyst Rating
View moreForecast & Rating
Oct 7, 2022Price forecast
--100.00%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 29 at 04:20 PM
PharmaCyte net loss widens to $19.42 million in FY26; revenue remains no revenue
- benzinga_article · Jun 2 at 04:09 PM
12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga_article · May 18 at 04:05 PM
12 Health Care Stocks Moving In Monday's After-Market Session
- prnewswire · May 5 at 06:38 AM
07:30 ETPackGene to Present Advances in Scalable AAV Manufacturing, Analytical Innovation, and Novel Capsid Engineering at ASGCT 2026
- Business Standard · Mar 17 at 04:51 PM
Mankind Pharma shares gain 3% on acquiring Rivotril brand rights from Roche
- TradingView · Mar 17 at 02:51 PM
PharmaCyte Biotech 10-Q: $0.0M Revenue, $(0.17) EPS (Q3), $(2.41) EPS (YTD)
